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2Abstract
Tissue engineering and regenerative medicine are rapidly developing fields that use cells or 
cell based constructs as therapeutic products for a wide range of clinical applications. Efforts 
to commercialise these therapies are driving a need for capable, scaleable, manufacturing 
technologies to ensure therapies are able to meet regulatory requirements and are 
economically viable at industrial scale production. We report the first automated expansion 
of a human bone marrow derived mesenchymal stem cell population (hMSCs) using a fully 
automated cell culture platform. Differences in cell population growth profile, attributed to 
key methodological differences, were observed between the automated protocol and a 
benchmark manual protocol. However, qualitatively similar cell output, assessed by cell 
morphology and the expression of typical hMSC markers, was obtained from both systems. 
Furthermore, the critical importance of minor process variation, e.g. the effect of cell seeding 
density on characteristics such as population growth kinetics and cell phenotype, was 
observed irrespective of protocol type. This work highlights the importance of careful 
process design in therapeutic cell manufacture and demonstrates the potential of automated 
culture for future optimisation and scale up studies required for the translation of 
regenerative medicine products from the laboratory to the clinic.
Key words: Cell culture automation, Commercialisation, Human mesenchymal stem cells, 
Manufacture, Regenerative medicine.
3Introduction
Regenerative medicine and tissue engineering are expanding research areas in which human 
cells or cell based constructs are being developed as potential therapeutic products. Clinical 
applications of cell based therapies are wide ranging, but are predominantly aimed at 
degenerative conditions, organ failure, and tissue damage. The prospective market demand 
for regenerative medicine and tissue engineered products is enormous; the waiting list for 
organs in the US has grown yearly from 43 000 at the end of 1995 to 91 000 at the end of 
2004 (2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and 
the Scientific Registry of Transplant Recipients). Intervertebral disc and articular cartilage 
degeneration are further example areas of high clinical demand where current interventions 
are unsatisfactory and cell based therapies hold promise (Mochida, 2005; Leo and Grande, 
2006). Aside from the clinical potential, greater understanding of the production of in vivo 
like tissues in vitro could also lead to development of improved pharmaceutical cell based 
assays for high throughput screening and lead optimisation.
Adult stem cells are promising candidates for cell therapies. They lack the ethical 
complications associated with embryo derived cells and yet retain significant ability to 
differentiate into different cell types. Human mesenchymal stem cells (hMSCs) are an adult 
stem cell of particular interest; they can be isolated from bone marrow, multiplied relatively 
easily in vitro, and have the potential to differentiate into cells of the mesenchymal lineage 
many of which, such as cartilage, bone, or muscle, have large potential therapeutic markets 
(Pittenger et al., 1999). Recent studies have also reported that hMSCs can differentiate into 
important non-mesenchymal derived tissue types, such as hepatocyte like cells (Lee et al., 
2004) and neural like cells (Wang et al., 2007), and are potentially valuable in promoting 
4angiogenesis (Chen et al., 2007). Furthermore, these cells have immunomodulatory 
properties indicating possible application for allogeneic as well as autologous therapies 
(Sotiropoulou et al., 2006). There is a growing list of candidate source tissues such as 
placenta (Miao et al., 2006), umbilical cord blood (Lee et al., 2004), and adipose tissue (Zuk 
et al., 2001) that promise both easy access to and plentiful yields of hMSCs for cell based 
therapies. 
Following the isolation of a therapeutic cell type it is likely that cells will require expansion 
in vitro to provide sufficient functional biological material for a cell based therapy. 
Currently, most such culture processes are conducted at laboratory bench scale by a manual 
operator. The quality of the output is assured based on designed capability and quality 
control at each of the process steps; such consistent production capability is at the core of 
cGMP manufacturing regulations. The critical importance of such consistent processes for 
the manufacture of cell based therapies is demonstrated by the loss of hMSCs potential to 
differentiate into multiple cell types with successive passages at a rate dependent on culture 
conditions (Banfi et al., 2000; Izadpanah et al., 2006; Shahdadfar et al., 2005). Despite the 
diversity of cell therapies, they are united by such complexities surrounding production 
processes. It is important for a capable, scaleable manufacturing processes to be developed 
as an integral part of a cell based therapy to prevent a therapeutically or scientifically sound 
product from becoming a commercial failure. 
Automated cell culture is anticipated to have an important role in overcoming issues 
associated with the translation of current and emerging regenerative medicine technologies 
to the clinic, particularly through improving process capability, enabling culture scale up 
with controlled cost, and providing a stable high volume platform for understanding process 
5variation and subsequent process optimisation (Archer & Williams, 2005; Terstegge et al, 
2007). Automated production of cell products will have to be sufficiently consistent to 
ensure therapeutic utility and safety, with quality assurance measures commensurate with the 
potential consequences of administering a defective product. The application of automated 
cell culture to cell based therapies will therefore require great stringency in process control 
and validation to satisfy the high regulatory hurdles being set for the industry (British 
Standards Institute, 2006; Federal Drug Administration, 1997). Culture process optimisation 
work will therefore require capable cell culture process responses for assessing cell 
character. The ideal quality response for hMSCs, differentiation of cells to appropriate 
lineages, would be limiting for process engineering optimisation techniques due to low 
sensitivity (due to differentiation process variability) and subjective poor quantitative 
measurement systems. Unfortunately, a quantifiable marker that defines the potency of an 
expanded hMSC population has not yet been validated. However, there is substantial 
evidence that STRO-1 and ALP can respectively be used as markers of hMSC progenitor 
status and osteogenic progenitor differentiation respectively (Gronthos et al, 1999; Dennis et 
al, 2002; Stewart et al, 2003; Song et al, 2005). Combined with other typical hMSC markers, 
such as CD105 and CD166, an indicative, but not definitive, hMSC profile can be defined 
(Fibbe et al, 2002).
The objective of this work was to a convert a manual hMSC culture protocol, complete with 
the alterations necessitated by the automation, to a fully automated culture process. The 
automated process was assessed against a conventional manual culture to ensure the cell 
product was sufficiently similar to the product of the manual benchmark protocol to justify 
the initiation of systematic automated optimisation studies. Cell number, hMSC markers 
CD105, CD166, STRO-1 and the osteogenic marker ALP were used as process responses. 
6Experiments were conducted using two separate hMSC samples. The initial sample was used 
to establish appropriate cell seeding densities using automated and manual culture protocols. 
The second sample was used to conduct a parallel multi-batch culture of the automated and 
benchmark manual protocols. 
7Methods
Mononuclear Cell Isolation
Two samples of fresh human adult bone marrow (25 ml) were obtained from Cambrex (First 
sample donor: Age: 26, Sex: Male, Ethnicity: African, 22 x 106 cells/ml. Second sample 
donor: Age: 28, Sex: Female, Ethnicity: Caucasian, 17 x 106 cells/ml). Bone marrow was 
diluted with an equal volume of DMEM-LG-10FB (Dulbecco’s Modified Eagle’s Medium 
with 1.0g/l glucose (Cambrex), 10% Foetal Calf Serum MSC qualified (Invitrogen-Gibco), 
1% 100x antibiotic/antimycotic (Invitrogen) (final concentrations 100U/ml penicillin, 
100µg/ml streptomycin and 0.25µg/ml Amphotericin), 1% Glutamax-I (Invitrogen-Gibco), 
and 1% Non-Essential Amino Acid mixture (Cambrex)). This mixture was split between two 
Accuspin™ tubes (Sigma-Aldrich) containing 15 ml Histopaque and centrifuged on a swing-
arm rotor at 800 g for 20 minutes. The opaque layer of mononuclear cells (MNCs) was 
transferred to a new tube, washed with 10 ml DMEM-LG-10FB, centrifuged at 300 g for 10 
minutes, resuspended in 30 ml DMEM-LG-10FB, and then counted using a Cedex 
automated cell counter (average of 20 images, analysis software std ver. 05).
Cell culture protocols
MNCs from the first sample were seeded in 40 ml DMEM-LG-10FB in T175 flasks (Primo 
culture, P0) at a number of cell seeding densities to reflect the range reported in the literature 
(6 000, 13 000, 25 000, 80 000 and 200 000 cells/cm2). Cultures were conducted in parallel 
using an automated (CompacT SelecT) and a manual protocol. DMEM-LG-10FB (25 ml) 
was added on the 2nd day and the 5th day after seeding. Media was removed and replaced 
8with fresh DMEM-LG-10FB (40 ml) on the 8th day after seeding. Adherent cells (hMSCs) 
were passaged according to protocol below (P1 denotes passage number) on the 12th day 
after isolation and daughter flasks seeded at 2500, 6000, or 8000/cm2. All culture 
manipulation was manual from this point. At P2 the daughter flasks were all seeded at 
5000/cm2. Media was removed and replaced with fresh media on the 3rd day after each 
passage and a further passage conducted on the 7th day. This was repeated up to P3.
MNCs from the second sample were seeded in T175 flasks at densities guided by the first 
experiments (20 000/cm2 at P0, 2500/cm2 at P1 and thereafter) and cultured in parallel using 
manual and automated protocols. Other than cell seeding densities, the same passage 
protocol and media change regimen was followed as for the first sample. 
Manual passage protocol: Following aspiration of media from the flask, cells were incubated 
with 10 ml Trypsin (2.5 g/l)/EDTA (0.2g/l) (SigmaAldrich) at 37ºC and 5% CO2 . After 10 
minutes, the flask was tapped to help cell detachment, and then cells were resuspended in 
DMEM-LG-10FB (20ml) and centrifuged at 300 g. Cells were resuspended in fresh DMEM-
LG-10FB and a sample transferred to a Cedex automated cell counter for counting. An 
aliquot of cells were then seeded in DMEM-LG-10FB (40 ml) in T175 flasks at densities 
specified. 
Automated passage process: The CompacT SelecT carried out a fully automated passage 
process as similar as possible to the manual. The machine consists of a robot arm in a class II 
laminar flow cabinet that can access a T175 flask incubator. The automated process included 
minor procedural differences from the manual included emptying of media from flasks 
instead of aspiration and pumping of liquids through lines instead of pipetting. The major 
9procedural difference was after the incubation with trypsin and neutralisation with DMEM-
LG-10FB (20 ml). Instead of centrifugation and re-suspension (and hence removal of trypsin 
residue) cells were immediately counted using the Cedex cell counter, then diluted (volume 
variable depending on cell concentration) further with DMEM-LG-10 FB to achieve a 50
000 cell/ml suspension. 8.75 ml of this suspension was seeded in to a new flask and diluted 
with 31.25 ml DMEM-LG-10FB to give a seeding density of 2500/cm2. Trypsin 
contamination was calculated to be approximately 2%.
Alkaline phosphatase activity
Cells from P1 (sample 1) were plated at 1000/well of a 96 well plate and cultured in 200 µl 
of control (DMEM-LG-10FB) or inductive media (DMEM-LG-10FB with 10 nM 
dexamethasone) for 4 days (6 replicate wells/flask). Cells were then incubated at room
temperature for 1 hour in 100 µl substrate solution (Sigmafast™ tablets: made up to give 
1.0mg/ml P-nitrophenyl phosphate (ALP substrate) in 0.2 M TRIS buffer and 5mM 
magnesium chloride). After incubation sample absorbance was read on an Eltax 800 
microplate reader at 405 m wavelength.
Flow Cytometry
Cells were prepared for flow cytometry by centrifuging at 300 g. Supernatant was discarded 
and cells were resuspended in phosphate buffered saline (PBS) and re-spun at 300 g. 
Supernatant was discarded and cells were re-suspended in Pharmingen stain buffer (BD 
biosciences) at 8.3 x 105 cells per ml. 10 µl of anti-human CD105-PE (Beckman Coulter, 
clone 1G2), CD166-PE, STRO-1-FITC (R&D Systems, clone STRO-1), or ALP-PE (R&D 
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systems, clone B4-78) antibody was added to a 300 µl aliquot of this suspension and 
incubated at room temperature for 20 minutes. Negative controls were incubated without 
antibody. Samples were centrifuged at 300 g and re-suspended in 300 µl Pharmingen stain 
buffer. Samples were analysed on a Beckman Coulter Quanta SC Flow Cytometer. 
Trypsin contamination
Cells from P3 hMSC culture were seeded at 2500/cm2 into T25 flasks. Cells were cultured 
for 3 days in DMEM-LG-10FB containing 15%, 10%, 5%, 2%, 1%, 0.5% or 0% 
Trypsin(0.25%)/EDTA solution. At the end of this period cells were passaged and counted 
using the Cedex automated cell counter to assess growth.
Experimental design
The first MNC sample was used to seed ten P0 flasks at different seeding densities; five 
flasks were cultured using the manual protocol and five parallel flasks were cultured using 
the automated protocol. MNC seeding densities at P0 were not replicated due to practical 
constraints and cost/quantity of the sample. At P1 enough cells were present to conduct 
seeding density experiments in duplicate or triplicate (see results). Cells from the second 
MNC sample were seeded into twelve flasks; eight replicate batches were cultured using the 
automated protocol and four replicates batches cultured using the manual protocol. Each 
replicate was kept independent at each successive passage, i.e. were not pooled, to allow a 
multi-batch comparison of extended culture. Where appropriate Microsoft Excel was used to 
calculate Student’s T-test P-values.
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Results
Establishing cell culture parameters
The first MNC sample was used to establish the most appropriate cell seeding density for the 
automated and manual cell culture protocols. Successful cell growth was observed between 
P0 and P1 using both protocols. An inverse relationship was observed between cell seeding 
density at P0 and population growth kinetics irrespective of protocol (fig 1). At seeding 
densities of approximately 25 000 cells/cm2 and below, the ratio of adherent cells harvested 
at P1 to MNCs seeded at P0 was similar. At MNC seeding densities above 25 000 cells/cm2
a trend of reduced adherent cells per MNC seeded was observed for both protocols. 
A comparison of seeding densities and the effect on cell growth was conducted in the 
manual culture system at P1 and P2. A similar qualitative relationship between cell seeding 
density and cell population growth was observed as at P0 (fig 2). The lower the seeding 
density at P1 the faster the population expansion at P2 and P3. No minimum seeding density 
for successful growth was observed in the range encompassed by these experiments. 
Baseline and induced ALP activity were measured to indicate whether the cells were 
differentiating down the osteogenic lineage (identified by increased ALP expression) and 
hence losing multipotency, a tendency of hMSCs in culture (fig 3).  The higher the density of 
cell culture between P0 and P1 the higher the level of baseline ALP observed and the lower 
the inducibility of ALP observed relative to baseline activity. 
Multi-batch automated and manual hMSC culture: growth profile and cell product
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A multi-batch experiment was conducted to investigate cell population growth profiles in 
cultures using automated and benchmark manual protocols and seeding densities guided by 
the previously described experiments (20 000/cm2 at P0, 2500/cm2 thereafter). As observed 
in the first experiment, the cell population growth up to P1 was similar for both manual and 
automated culture (P=0.99). However, after P1 the growth profiles differ (P2; P=0.0001, P3; 
P=0.11, P4; P=0.001) (fig 4). The peak growth rate in the manual culture, between P1 and 
P2, was both earlier and higher than that of automated culture which achieved a peak growth 
rate in the period between P2 and P3. At P4 however, cells in automated culture were 
proliferating faster than cells in manual culture.
Cells cultured using automated and manual protocols were compared microscopically for 
morphological variation. The cell product from each system was also compared for 
expression of the typical hMSC surface markers CD 105, CD 166, STRO-1, and osteogenic 
differentiation marker ALP at the end of the culture process (P4) using flow cytometry. Cells 
generated by manual or automated culture protocols were morphologically similar (fig 5). 
The cells generated from automated culture were observed to have a slightly more spread 
morphology compared to a more spindle-like morphology in cells from manual culture. Cells 
generated from both culture systems ubiquitously expressed the markers CD 105 and CD 
166. However, the manually cultured cells had significantly higher levels of STRO-1 
(P≤0.05) and statistically insignificantly higher levels of ALP expression (P=0.15) (Table 1).
Investigation of the effect of trypsin/EDTA on cell population growth
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The observed difference in growth profile between manual and automated culture and the 
difference between the trypsinisation sub-process in manual and automated culture prompted 
an investigation into the effect of potential contamination by residual trypsin in the 
automated culture process. Lower cell population growth was observed in flasks containing 
trypsin/EDTA in a concentration dependent manner (fig 6).
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 Discussion
In this paper we demonstrate the successful culture of adult human mesenchymal stem cells 
using an automated cell culture platform. We highlight the impact that some procedural 
differences between the automated culture protocol and a benchmark manual system have on 
cell production. Furthermore, we demonstrate the sensitivity of the cell output to culture 
parameters and the consequent importance of stable processes. Finally we discuss these 
experimental observations in relation to the potential for cell culture automation applied to 
production of cells for cell based therapies.
A manual method for hMSC culture was successfully automated using an automated culture 
platform, the CompacT SelecT. This demonstrates the potential of such scaleable systems as 
platforms for production of adult stem cells in sufficient volumes for therapeutic use. 
However, this demonstration has also raised questions regarding the effect on the cell 
product of differences between the benchmark manual culture process and the automated 
culture process. The similarity in population growth of cells in manual and automated culture 
up to the first passage suggest that the observed difference in growth profile after this may be 
attributable to methodological differences introduced at the passage point. The most obvious 
such difference is the lack of centrifugation to remove residual trypsin/EDTA in the 
automated trypsinisation sub-process. The automated process relies on inactivation of 
trypsin/EDTA through substrate saturation by excess protein in the culture media as well as 
relatively rapid auto-digestion. However, our preliminary investigation of trypsin 
contamination and cell population growth suggest that the levels of residual trypsin/EDTA 
present in the automated protocol (typically 1-4%) would inhibit hMSC growth and 
trypsin/EDTA residue is therefore likely to be contributing to differences observed between 
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culture protocols. The level of trypsin/EDTA contamination is hard to control in automated 
culture, as the dilution is dependent on the cell yield from the passage indicating it would be 
an issue for developing a controlled process. It provides an example of the level of process 
control that will be required for reproducible production of sensitive cell types. The different 
growth profile between manual and automated protocols after the first passage suggests that 
the earlier, faster, cell proliferation in the manual culture either uses a finite ‘growth 
potential’, or that the manual cell population growth potential is damaged by the faster 
proliferation or higher cell density reached resulting in lower growth later in culture. If the 
former were true it is possible that the automated protocol does not reduce the proliferative 
potential of the cells, but would produce the same yield over a longer time. However, 
process time and consequent cost will be an important parameter for industrial production 
and some clinical applications.
Cell seeding density was identified as an important parameter that influenced growth and 
functionality characteristics of the cell product. This may be due to a number of factors such 
as nutrient supply and cell-to-cell communication affecting proliferation or initial cell 
adherence. The issue of seeding density is complicated by the tendency of hMSCs to grow in 
closely associated colonies in early culture and in more disperse monolayer in later culture 
suggesting the effect of culture density may vary depending on culture age and condition. 
Importantly, this work suggests that sparser culture of hMSCs may be better for producing a 
more replicative, less differentiated cell product and identifies this culture parameter as an 
important target for further optimisation work. 
The difference between the linear relationship between cell seeding density and alkaline 
phosphatase activity and the non-linear relationship between cell seeding density and cell 
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yield emphasises the importance and complexity of choosing an endpoint for assessing 
culture protocols. Although cell cultures seeded at densities of 25 000/cm2 or less yielded an 
equivalent number of adherent cells per MNC seeded, baseline alkaline phosphatase activity 
was reduced and the induced level relatively increased in cultures with seeding densities less 
than 25 000/cm2. This implies that seeding densities selected on the basis of equivalent cell 
yields could still produce cells in a variable state of differentiation, and, therefore, with 
variable therapeutic potential. The importance of selecting endpoints that are sensitive and 
relevant to the cells intended use is further emphasised by the lack of difference observed in 
expression of common hMSC surface markers (CD 105 and CD 166) between cells cultured 
with different protocols, despite the observed difference in cell yields. In contrast, STRO-1 
and ALP expression are sensitive to process differences and therefore may be suitable 
candidate indicators for culture process optimisation. They indicate only a proportion of the 
adherent cells are hMSCs and a large proportion have begun to differentiate down the 
osteoblast lineage. Defining such product endpoints to ensure safety and efficacy is 
complicated by many factors including the evolving requirements of the immature 
regenerative medicine industry (both clinical and regulatory), the paucity of specifications 
traceable to clinical need, the heterogeneous and unstable nature of many therapeutic cell 
types, and the lack of suitably authoritative measurement systems.
This work shows the potential of an automated cell culture platform for growing 
therapeutically significant human cells for regenerative medicine and tissue engineering 
applications. The need for detailed understanding of processes, process optimisation and 
process standardisation, is highlighted by the demonstrable alteration of cell population 
characteristics by small methodological variations. As cell therapy products these 
populations would be anticipated to respond differently when applied in regenerative 
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medicine or tissue engineering applications giving rise to clinical, regulatory and 
industrialisation cost issues. The process stability provided by automation will allow 
complex multi-factorial optimisation studies and, it is thought, give a natural transition to 
early clinical stage production capable of satisfying stringent regulatory requirements. This 
work lays the foundations for further automated studies to identify, understand, and optimise 
the key methodological parameters for controlling cell output, defined by therapeutically 
significant markers or functions, of processes for building regenerative medicine products. 
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Figure Captions:
Figure 1: hMSC yield at P1 per 1000 MNCs seeded at P0 for a range of P0 MNC seeding 
densities cultured using an automated or manual protocol (sample 1). Cell seeding above 
25000/cm2 reduces the yield of hMSCs per MNC seeded.
Figure 2: hMSC population expansion between P1 and P2 and between P2 and P3 related to 
seeding density at P1 (sample 1). Cell populations expand faster when seeded at a lower 
density. Each data point represents an individual flask.
Figure 3: Baseline and induced alkaline phosphatase activity in adherent cells cultured at 
various densities. Higher ALP activity indicates increased commitment to the osteogenic 
lineage in cells cultured at higher densities (sample 1)
Figure 4: hMSC yield per T175 flask at each passage from cells grown using an automated 
or manual protocol (sample 2). Growth profiles differ between protocols. Error bars show 
the standard error of the mean. Automated culture (n=8), manual culture (n=4).
Figure 5: A representative selection of images of cells cultured using automated (A) and 
manual (M) culture protocols. 1: Closely associated cells in colony centres immediately prior 
to P1, 2: Cells in monolayer prior to P2, 3: Cells in monolayer prior to P3. Cells are 
morphologically similar at all points (sample 2). 
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Figure 6: Cell population growth in manual culture exposed to a range of trypsin/EDTA 
concentrations in the culture media. Cells grow slower the higher the level of contamination. 
Each data point is an average of three flasks.
Table captions
Table 1: The percentage of cells from P4 automated or P4 manual culture expressing hMSC 
markers  CD105 (P≤0.05), CD166, STRO-1 or ALP. 
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Table 1
Surface Marker Percentage of cells expressing 
(manual culture)
Percentage of cells expressing 
(automated culture)
CD166 100 100
CD105 100 100
ALP 46.28 39.43
STRO-1 9.16 5.28
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Figure 2
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Figure 3
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Figure 5
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